Informatics researcher to play a role in a newly established Micro-Tex Hub

[16/10/2024] Dr Mohsen Khadem takes on the role of the industrial and translational lead for the Edinburgh-led MicroTex Hub, a multi-million Edinburgh-led initiative that will focus on speeding up the creation of new treatments for lung infections and inflammation.

The Research and Partnership Hub in Microscale Science and Technology to Accelerate Therapeutic Innovation (MicroTex) unites engineering with robotics, AI chemistry, physics, biology and clinical medicine.

Dr Mohsen Khadem

Translating research into application

In this role, Mohsen will help guide the translation of research into practical applications, ensuring that the technologies developed within the hub, particularly those focused on accurate and repeatable drug delivery to hard-to-reach areas of the body, can be effectively moved toward industrial use and clinical practice.  

The hub benefits from Dr Khadem’s prior work during his UKRI FLF fellowship, where he developed an AI-enabled robotic platform for drug delivery to the distal lung. This platform aims to improve targeted treatments, especially for lung infections and inflammation. 

Collaborative research

MicroTex is led by the University of Edinburgh, and based in the Baillie Gifford Pandemic Science Hub in the Institute of Regeneration and Repair. Partners include the University of Bath and Heriot-Watt University, LifeArc Rare Respiratory Diseases Centre, Baillie Gifford, patient groups, international and industrial collaborators. 

The Hub will be funded for the next six years by the Engineering and Physical Sciences Research Council (EPSRC). It will receive £11 million from the government supported by £16.6 million from partner funders. 

In a post-Covid world, the urgency to outpace infectious and inflammatory diseases and be prepared for the next pandemic, has never been greater. The MicroTex hub will deliver a critical leap forward in this race. The Hub brings together a highly diverse team of researchers and a wide range of partners to innovate, collaborate and transform drug development with microdosing. 

These innovative technologies have the potential to improve patient care in the UK and around the world. By investing in this research, we are enabling scientists to develop life-changing technologies. 

Related links